

**Amendments to the Claims:**

This listing of claims will replace all prior versions, and listings of claims in the application:

**Listing of Claims:**

1-35. (Canceled)

35. (New) An isolated polynucleotide comprising a smooth muscle cell myosin heavy chain (SM-MHC) promoter/enhancer, wherein the enhancer comprises the rat or human sequence depicted in Figure 18(b), and the promoter comprises a heterologous TATA box or transcription initiation site, and wherein the promoter/enhancer initiates expression in a smooth muscle cell *in vivo* when introduced into an animal.

36. (New) The polynucleotide of claim 35, wherein the promoter comprises a CArG1 and/or a CArG2 motif.

37. (New) The polynucleotide of claim 35, wherein the promoter is coupled to a minimal thymidine kinase (TK) promoter.

38. (New) The polynucleotide of claim 35, wherein the promoter is operably linked to a heterologous polynucleotide.

39. (New) The polynucleotide of claim 38, wherein the heterologous polynucleotide encodes a polypeptide.

40. (New) An isolated polynucleotide comprising a smooth muscle cell myosin heavy chain (SM-MHC) promoter/enhancer, wherein the promoter/enhancer sequence comprises SEQ ID NO:16 or SEQ ID NO:17, wherein a CArG2 or intronic CArG motif is mutated and wherein the promoter is expressed in a subset of smooth muscle cells *in vivo* when introduced into an animal.

41. (New) The polynucleotide of claim 40, wherein the CArG2 motif is mutated.

42. (New) The polynucleotide of claim 40, wherein the intronic CArG motif is mutated.
43. (New) The polynucleotide of claim 40 wherein promoter is operably linked to a heterologous polynucleotide.
44. (New) The polynucleotide of claim 40, wherein the heterologous polynucleotide encodes a polypeptide.
45. (New) A genetically engineered cell comprising the polynucleotide of claim 35 or 40.
46. (New) A composition comprising the polynucleotide of claims 35 or 40 in a pharmaceutically acceptable carrier.
47. (New) An isolated polynucleotide comprising a smooth muscle cell myosin heavy chain (SM-MHC) promoter/enhancer, wherein the promoter/enhancer sequence comprises:  
nucleotides 1 to 6700 and 11,700 to 13,700 of SEQ ID NO:16 and does not comprise the intervening nucleotides; or  
nucleotides 1 to 6700 and 9,500 to 15,800 of SEQ ID NO:16 and does not comprise the intervening nucleotides; and  
wherein the promoter/enhancer comprises a mutated or unmutated CArG2 or intronic CArG motif and the promoter/enhancer initiates expression in a subset of smooth muscle cells *in vivo* when introduced into an animal.
48. (New) The isolated polynucleotide of claim 47, wherein the promoter/enhancer comprises nucleotides 1 to 6700 and 11,700 to 13,700 of SEQ ID NO:16 and does not comprise the intervening nucleotides.
49. (New) The isolated polynucleotide of claim 47, wherein the promoter/enhancer comprises nucleotides 1 to 6700 and 9,500 to 15,800 of SEQ ID NO:16 and does not comprise the intervening nucleotides.

50. (New) The isolated polynucleotide of claim 47, wherein the promoter/enhancer initiates expression in gastrointestinal, airway, arteriolar, and bladder smooth muscle cells but does not initiate expression in vascular smooth muscle cells within large arteries.
51. (New) The isolated polynucleotide of claim 47, wherein the promoter/enhancer comprises a mutated CArG2 motif.
52. (New) The isolated polynucleotide of claim 47, wherein the promoter/enhancer comprises an unmutated CArG2 motif.
53. (New) The isolated polynucleotide of claim 47, wherein the promoter/enhancer comprises a mutated intronic CArG motif.
54. (New) The isolated polynucleotide of claim 47, wherein the promoter/enhancer comprises an unmutated intronic CArG motif.
55. (New) The isolated polynucleotide of claim 53, wherein the promoter/enhancer initiates selective expression in vascular smooth muscle in arterioles and airway smooth muscle.
56. (New) The isolated polynucleotide of claim 51, wherein the promoter/enhancer initiates selective expression in gastrointestinal smooth muscle.
57. (New) A genetically engineered cell comprising the polynucleotide of claim 47.
58. (New) A composition comprising the polynucleotide of claim 47 in a pharmaceutically acceptable carrier.